Christopher A. Yasenchak, MD

Articles by Christopher A. Yasenchak, MD

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

May 8th 2020

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin Lymphoma

ByChristopher A. Yasenchak, MD

January 23rd 2020

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCL

ByChristopher A. Yasenchak, MD

February 17th 2016

Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.